Avalanche Biotechnologies

Avalanche Biotechnologies is a publicly traded (NASDAQ:AAVL)[1] biotechnology company in the NASDAQ Biotechnology Index that is worth 245 million that is dedicated to diseases of the eye.[2] This includes macular degeneration,[3] retinal vein occlusion,[4] diabetic macular edema,[5] and others.[6]

References

  1. ↑ "Avalanche Biotechnologies, Inc (AAVL)". NASDAQ.com. Retrieved 4 January 2016.
  2. ↑ "Avalanche Biotechnologies Announces Leadership Transition". www.reuters.com. Retrieved 4 January 2016.
  3. ↑ "Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug? - Avalanche Biotechnologies (NASDAQ:AAVL)". Seeking Alpha. Retrieved 4 January 2016.
  4. ↑ Burger, Danielle. "Avalanche Drops as Gene Therapy Data Miss High Expectations". Bloomberg.com.
  5. ↑ "Update on the latest in business:". WTOP. Tegna Media. Retrieved 4 January 2016.
  6. ↑ Burger, Danielle. "Avalanche drops eye drug trial, takes it back to lab". CNBC.
This article is issued from Wikipedia - version of the 10/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.